Bionomics Completes Last Patient Last Visit In Phase 2 Attune Study Of BNC210 In Post Traumatic Disorder Stress, Topline Results Are Expected By The End Of September 2023
Portfolio Pulse from Benzinga Newsdesk
Bionomics has completed the last patient visit in its Phase 2 Attune study of BNC210 for Post Traumatic Disorder Stress. Topline results are expected by the end of September 2023. An end-of-phase 2 meeting with the FDA has been scheduled for September 2023 to review results from the Phase 2 PREVAIL study in patients with Social Anxiety Disorder and to obtain feedback on a proposed Phase 3 registrational program.
August 23, 2023 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bionomics has completed a significant phase in its clinical trials, which could potentially impact its stock positively if the results are favorable. The scheduled FDA meeting could also influence the stock depending on the feedback received.
The completion of a clinical trial phase and the anticipation of results often lead to speculation and potential positive movement in a biotech company's stock. The scheduled FDA meeting adds another layer of potential impact, as positive feedback could further boost investor confidence.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100